BlueWillow Biologics demonstrated the safety and immunogenicity in humans of the company’s intranasal technology, which CEO Chad Costley said is the only adjuvanted intranasal platform that is not virus-based.
Angany entered a partnering agreement to evaluate the safety and efficacy of the French-Canadian pharmaceutical company’s lead peanut allergy biological candidate BP/AH-01 with the Food Allergy Center at Massachusetts General Hospital and MassGeneral Hospital for Children.
DBV Technologies unveiled a global restructuring plan that will result in a reduction of more than 200 jobs.
BioSpace reviewed the top 10 novel drug approvals of 2020, loosely based on projected earnings in the upcoming years.
The European Commission approved Aimmune Therapeutics Inc.’s Palforzia for the treatment of peanut allergy.
The U.S. Food and Drug Administration issued a Complete Response Letter regarding DBV Technologies’ Biologics License Application (BLA) for investigational Viaskin Peanut (DBV712), a non-invasive, once-daily epicutaneous patch to treat peanut allergies in children ages 4 to 11 years.
Treatments for peanut allergy and Parkinson’s disease are among U.S. drug launches that have been postponed by the COVID-19 pandemic as drugmakers struggle with disruptions to business, a Reuters review of filings and interviews with executives show.
DBV Technologies is cutting jobs while awaiting news from the U.S. Food and Drug Administration about the company’s approval application for Viaskin Peanut.
Aimmune Therapeutics Inc. said 80 percent of patients being treated with the company’s Palforzia were successfully desensitized to peanut proteins after two years of daily dosing.
The U.S. Food and Drug Administration approved Aimmune Therapeutics’ oral immunotherapy Palforzia as a first-of-its-kind treatment for the millions of people suffering from an allergy to peanuts.